Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors

Aroa Soriano, Marc Vendrell, Sergio Gonzalez, Josefa Mallol, Fernando Albericio, Miriam Royo, Carmen Lluís, Enric I. Canela, Rafael Franco, Antoni Cortés and Vicent Casadó
Journal of Pharmacology and Experimental Therapeutics March 2010, 332 (3) 876-885; DOI: https://doi.org/10.1124/jpet.109.158824
Aroa Soriano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Vendrell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sergio Gonzalez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josefa Mallol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Albericio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Royo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carmen Lluís
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enric I. Canela
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rafael Franco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoni Cortés
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vicent Casadó
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The indoloquinolizidine-peptide 28 [(3S,12bR)-N-((S)-1-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(4-fluorophenyl)-1-oxopropan-2-ylamino)-4-cyclohexyl-1-oxobutan-2-yl)-1,2,3,4,6,7,12, 12b-octahydroindolo[2,3-a]quinolizine-3-carboxamide], a trans-indoloquinolizidine-peptide hybrid obtained by a combinatorial approach, behaved as an orthosteric ligand of all dopamine D2-like receptors (D2, D3, and D4) and dopamine D5 receptors, but as a negative allosteric modulator of agonist and antagonist binding to striatal dopamine D1 receptors. Indoloquinolizidine-peptide 28 induced a concentration-dependent hyperbolic increase in the antagonist apparent equilibrium dissociation constant values and altered the dissociation kinetics of dopamine D1 receptor antagonists. The negative allosteric modulation was also found when agonist binding to D1 receptors was assayed. Indoloquinolizidine-peptide 28 was a weak ago-allosteric modulator but markedly led to a decreased potency without decreasing the maximum partial/full agonist-mediated effect on cAMP levels. Compounds able to decrease the potency while preserving the efficacy of D1 receptor agonists are promising for exploration in psychotic pathologies.

Footnotes

  • This work was supported by the Spanish Ministerio de Ciencia y Tecnología [Grants SAF2008-00146, SAF2009-07276] (to E.I.C. and R.F., respectively); and Fundació La Marató de TV3 [Grant 060110 ] (to E.I.C.).

  • Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.

    doi:10.1124/jpet.109.158824.

  • ↵Embedded Image The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.

  • ABBREVIATIONS:

    GPCR
    G-protein-coupled receptor
    IP28
    indoloquinolizidine-peptide 28, (3S,12bR)-N-((S)-1-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)- 3-(4-fluorophenyl)-1-oxopropan-2-ylamino)-4-cyclohexyl-1-oxobutan-2-yl)-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizine-3-carboxamide (C40H51FN6O4)
    SCH 23390
    R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
    SKF 38393
    2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
    SKF 81297
    (±)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide
    A77636
    (1R,3S)-3-(1′-adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran
    SKF 83566
    8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benza zepin-7-ol hydrobromide
    YM-09151–2
    cis-5-chloro-2-methoxy-4(methylamine)-N-[2-methyl-1-(phenylmethyl)-3-pyrrolidinyl]benzamide
    HBSS
    Hank's balanced salt solution
    FRT
    Flp recombination target
    HEK
    human embryonic kidney.

    • Received July 13, 2009.
    • Accepted December 17, 2009.
  • Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 381 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 381, Issue 2
1 May 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors

Aroa Soriano, Marc Vendrell, Sergio Gonzalez, Josefa Mallol, Fernando Albericio, Miriam Royo, Carmen Lluís, Enric I. Canela, Rafael Franco, Antoni Cortés and Vicent Casadó
Journal of Pharmacology and Experimental Therapeutics March 1, 2010, 332 (3) 876-885; DOI: https://doi.org/10.1124/jpet.109.158824

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

A Hybrid Indoloquinolizidine Peptide as Allosteric Modulator of Dopamine D1 Receptors

Aroa Soriano, Marc Vendrell, Sergio Gonzalez, Josefa Mallol, Fernando Albericio, Miriam Royo, Carmen Lluís, Enric I. Canela, Rafael Franco, Antoni Cortés and Vicent Casadó
Journal of Pharmacology and Experimental Therapeutics March 1, 2010, 332 (3) 876-885; DOI: https://doi.org/10.1124/jpet.109.158824
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antipsychotic-VMAT2 Inhibitor Synergy: Schizophrenia Models
  • Rescue Pharmacology on Disease-Related GRIN Variants
  • Obesity thwarts preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics